Home › Funds › TENOR CAPITAL MANAGEMENT Co., L.P. › BMRN

TENOR CAPITAL MANAGEMENT Co., L.P. position in BMRN

BIOMARIN PHARMACEUTICAL INC COM · Health Care

TENOR CAPITAL MANAGEMENT Co., L.P. reported holding 111,500,000 shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM) in its Q2 2026 13F filing — a position valued at US$108.9M, representing 2.02% of its reported portfolio and ranking #7 among its reported holdings. TENOR CAPITAL MANAGEMENT Co., L.P. has disclosed BMRN holdings in 8 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)111.50M sh
Reported value held$108.89M
Portfolio Weight2.02%
First reportedQ4 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How TENOR CAPITAL MANAGEMENT Co., L.P.'s BMRN position evolved

TENOR CAPITAL MANAGEMENT Co., L.P. first disclosed a stake in BMRN in Q4 2023 at 2,932,000 shares (US$2.90B). The position peaked in Q2 2024 at 23,693,000 shares, worth US$23.65B. Across 8 filings, TENOR CAPITAL MANAGEMENT Co., L.P. increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 111,500,000 shares valued at US$108.9M. Notable position changes include a 639% increase in Q1 2024 (shares fell 6% over the following quarter), a 32% increase in Q3 2025 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 2.93M $2.90B New
Q1 2024 21.66M $21.33B Add
Q2 2024 23.69M $23.65B Add
Q2 2025 77.58M $73.28M New
Q3 2025 102.08M $97.51M Add
Q4 2025 116.50M $112.24M Add
Q1 2026 111.50M $108.12M Reduce
Q2 2026 111.50M $108.89M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BMRN and 13F data

BMRN (BIOMARIN PHARMACEUTICAL INC COM) is a Health Care company. 26 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$812.0M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BMRN

All BMRN fund holders →

FAQ

How long has TENOR CAPITAL MANAGEMENT Co., L.P. held BMRN?

TENOR CAPITAL MANAGEMENT Co., L.P. has disclosed BMRN holdings in 8 of the last 11 reported quarters, going back to Q4 2023.

What is TENOR CAPITAL MANAGEMENT Co., L.P.'s current position in BMRN?

As of Q2 2026, TENOR CAPITAL MANAGEMENT Co., L.P. holds 111.50M shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM), valued at $108.89M, representing 2.02% of its reported portfolio and ranking #7.

Has TENOR CAPITAL MANAGEMENT Co., L.P. been buying or selling BMRN?

In the latest 13F filing (Q2 2026), TENOR CAPITAL MANAGEMENT Co., L.P. held unchanged its position in BMRN. The position peaked in Q2 2024 at 23.69M shares.

Which other funds hold BMRN?

Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 26 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.